NERVGEN PHARMA CORP (NGEN.CA) Fundamental Analysis & Valuation

TSX-V:NGEN • CA64082X2032

Current stock price

5.15 CAD
+0.15 (+3%)
Last:

This NGEN.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NGEN.CA Profitability Analysis

1.1 Basic Checks

  • In the past year NGEN has reported negative net income.
  • NGEN had a negative operating cash flow in the past year.
  • In the past 5 years NGEN always reported negative net income.
  • NGEN had a negative operating cash flow in each of the past 5 years.
NGEN.CA Yearly Net Income VS EBIT VS OCF VS FCFNGEN.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

  • NGEN has a worse Return On Assets (-197.42%) than 87.88% of its industry peers.
Industry RankSector Rank
ROA -197.42%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NGEN.CA Yearly ROA, ROE, ROICNGEN.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

  • NGEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NGEN.CA Yearly Profit, Operating, Gross MarginsNGEN.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. NGEN.CA Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for NGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NGEN.CA Yearly Shares OutstandingNGEN.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
NGEN.CA Yearly Total Debt VS Total AssetsNGEN.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

2.2 Solvency

  • NGEN has an Altman-Z score of -1.20. This is a bad value and indicates that NGEN is not financially healthy and even has some risk of bankruptcy.
  • NGEN's Altman-Z score of -1.20 is in line compared to the rest of the industry. NGEN outperforms 42.42% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.2
ROIC/WACCN/A
WACCN/A
NGEN.CA Yearly LT Debt VS Equity VS FCFNGEN.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

  • A Current Ratio of 0.79 indicates that NGEN may have some problems paying its short term obligations.
  • NGEN has a Current ratio of 0.79. This is amonst the worse of the industry: NGEN underperforms 87.88% of its industry peers.
  • NGEN has a Quick Ratio of 0.79. This is a bad value and indicates that NGEN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • NGEN has a Quick ratio of 0.79. This is in the lower half of the industry: NGEN underperforms 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 0.79
Quick Ratio 0.79
NGEN.CA Yearly Current Assets VS Current LiabilitesNGEN.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. NGEN.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 2.11% over the past year.
EPS 1Y (TTM)2.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 50.55% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y24.97%
EPS Next 2Y7.18%
EPS Next 3Y8.54%
EPS Next 5Y50.55%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NGEN.CA Yearly Revenue VS EstimatesNGEN.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
NGEN.CA Yearly EPS VS EstimatesNGEN.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. NGEN.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NGEN. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NGEN.CA Price Earnings VS Forward Price EarningsNGEN.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NGEN.CA Per share dataNGEN.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.18%
EPS Next 3Y8.54%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NGEN.CA Dividend Analysis

5.1 Amount

  • No dividends for NGEN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NGEN.CA Fundamentals: All Metrics, Ratios and Statistics

NERVGEN PHARMA CORP

TSX-V:NGEN (3/16/2026, 7:00:00 PM)

5.15

+0.15 (+3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-24
Earnings (Next)04-02
Inst Owners0.06%
Inst Owner ChangeN/A
Ins Owners2.74%
Ins Owner ChangeN/A
Market Cap414.78M
Revenue(TTM)N/A
Net Income(TTM)-25.82M
Analysts80
Price Target7.75 (50.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-78.22%
Min EPS beat(2)-157.43%
Max EPS beat(2)0.99%
EPS beat(4)2
Avg EPS beat(4)-43.47%
Min EPS beat(4)-157.43%
Max EPS beat(4)33.99%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.04%
EPS NQ rev (1m)-58.33%
EPS NQ rev (3m)-58.33%
EPS NY rev (1m)0%
EPS NY rev (3m)28.44%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.38
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0
BVpS-0.04
TBVpS-0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -197.42%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.79
Quick Ratio 0.79
Altman-Z -1.2
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)38.62%
Cap/Depr(5y)46.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y24.97%
EPS Next 2Y7.18%
EPS Next 3Y8.54%
EPS Next 5Y50.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-26.38%
OCF growth 3YN/A
OCF growth 5YN/A

NERVGEN PHARMA CORP / NGEN.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of NERVGEN PHARMA CORP (NGEN.CA) stock?

ChartMill assigns a fundamental rating of 0 / 10 to NGEN.CA.


What is the valuation status of NERVGEN PHARMA CORP (NGEN.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to NERVGEN PHARMA CORP (NGEN.CA). This can be considered as Overvalued.


What is the profitability of NGEN stock?

NERVGEN PHARMA CORP (NGEN.CA) has a profitability rating of 0 / 10.


What is the expected EPS growth for NERVGEN PHARMA CORP (NGEN.CA) stock?

The Earnings per Share (EPS) of NERVGEN PHARMA CORP (NGEN.CA) is expected to grow by 24.97% in the next year.